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Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but infor-
mation concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. 
Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 receptor (sIL-6R) in relation to re-
sponse to treatment with and plasma concentrations of anagrelide. Samples from 45 patients with thrombo-
cythemia due to MPD (ET=31, PV=14), being treated with anagrelide for 6 months, were analyzed for TPO, 
sIL-6R and anagrelide levels. The mean baseline platelet count was 983x109/L. A reduction of platelets to <600 in 
asymptomatic or <400 x 109/L in symptomatic patients was defined as a complete remission (CR), a reduction 
with >50% of baseline as partial remission, and <50% reduction as failure. At 6 months, 35 patients were in CR, 1 
had a partial remission and 9 were treatment failures. For all patients, there was an increase in TPO of 44% from 
baseline; this change was more pronounced for patients with partial remission and failure. sIL-6R levels did not 
change significantly. There was no correlation between levels of anagrelide and cytokine levels at 6 months, and 
changes of cytokine levels did not relate to changes of platelet counts. Thus, a pronounced increase of TPO levels 
after 6 months of anagrelide treatment indicated that this treatment affected a major regulatory mechanism for 
megakaryocyte and platelet formation in MPD. 
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Introduction 
One of the clinical challenges in chronic  mye-
loproliferative disorders (MPD) is thrombocythemia, 
always present in essential thrombocythemia (ET) and 
often in polycythemia vera (PV), myelofibrosis (MF) 
and chronic myelogenous leukemia. The risks associ-
ated with thrombocythemia are thromboembolic 
events and bleeding, risks that may be reduced with 
appropriate therapy. 
Anagrelide hydroxide is a platelet reducing 
compound, often used as an alternative to hydroxy-
urea, interferon-α and alkylating agents for the treat-
ment of thrombocytosis in MPD [1-4]. Anagrelide ex-
erts its effect by reducing differentiation at a late, 
non-mitotic stage in megakaryocyte development 
[5-8]. This leads to reduced platelet production by in-
hibition of megakaryocyte colony development, 
thereby reducing megakaryocyte size and ploidy, and 
disrupting or preventing full megakaryocyte matura-
tion. However, little is known of the interaction of 
anagrelide with cytokines regulating thrombocyto-
poiesis, particularly thrombopoietin (TPO), the major 
growth factor for regulation of blood platelet levels [9]. 
In a recent study a dose-response effect of anagrelide 
on CD41 numbers and TPO-specific pTyr activity was 
seen in vitro, indicating that anagrelide reduces the 
TPO-mediated intracellular signaling events [10]. 
Serum or plasma levels of TPO are often, but not 
always, raised in MPD [11-20; 21-25], with the highest 
levels being observed in MF [24, 26]. Likewise, TPO 
concentrations are often high in reactive thrombocyto-
sis [13, 14, 18, 22]. A few reports have described higher 
TPO levels in treated compared to untreated MPD 
patients [15, 17, 12]. In some of these studies, an in-
verse relation between blood platelet counts and TPO 
was observed [16, 26] but just as often there was no 
correlation [13, 19]. A role for TPO for emergence of 
MF has also been suggested, based on results from Int. J. Med. Sci. 2008, 5 
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studies with mice with engineered TPO overproduc-
tion [27-29]. Likewise, interleukin-6 (IL-6) levels might 
be raised in MPD [14].  
Since it is poorly known if therapy for thrombo-
cythemia affects TPO levels, we assessed the effects of 
6 months of anagrelide treatment of thrombocytosis in 
MPD patients on serum levels of TPO and the sIL-6 
receptor. The latter was chosen since some recent evi-
dence has been presented indicating that high levels of 
this receptor might be found in MPD and might be 
lowered during anagrelide therapy [14, 30].  
Results 
Summary of clinical treatment results 
A full description of these results is given in [3]. 
There was no significant difference in dose adminis-
tered to either the ET or PV patients (p=0.3). After 6 
months of therapy, 45 patients were still taking ana-
grelide, 29 with ET and 16 with PV. 35 of these patients 
had a CR, 1 a PR and 9 were failures. Serum samples 
from these patients were analyzed for cytokine levels. 
Fifteen patients of the original 60 had stopped ana-
grelide due to side effects or insufficient effect at tol-
erable dose. 
Blood platelet levels  
The starting venous blood platelet counts for the 
45 patients of the ET and the PV groups are given in 
Table 1, together with the platelet counts at 6 months. 
All 45 patients displayed a similar drop of the platelet 
count (Table 1). At start, there was no difference for the 
platelet counts for those achieving CR and those who 
did not (982 x 109/L for both groups). The drop of the 
platelet count over the 6 months was 50.3 % for all 45 
MPD patients, 56.6 % for patients achieving CR and 
29.4 % for the PR and F group (Figure 1). At 6 months, 
the difference between the CR and the PR+F groups 
(424±115 vs. 694±282) was statistically significant 
(P<0.01). 
Table 1. Platelet counts, serum TPO and sIL-6R concentrations 
prior to and after 6 months of anagrelide treatment. Mean and 
SD values. 
Platelets, 
x109/L 
At start  After 6 
months 
P values 
  All MPD pts  983±312 488±201  <0.000001 
 ET only 1005±328 489±189   
 PV only 937±284  496±246   
TPO, pg/mL       
  All MPD pts  71±89 103±100 0.00007 
 ET only 54.9±66.9 81.0±81.4   
 PV only 76.1±53.3 115±89.3   
sIL-6R, 
ng/mL 
   
  All MPD pts  38.5±9.9 37.4±8.4  0.087 
 ET only 36.7±9.4 36.0±7.6   
 PV only 42.2±10.9  41.0±9.6   
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Figure 1. Changes at 6 months in platelet counts, TPO and 
sIL-6R concentrations in all MPD patients (All), in those 
achieving complete response (CR) and those attaining partial 
response or failure of response (PR+F), in relation to values 
prior to start of anagrelide.  
 
Anagrelide concentrations 
At 6 months the mean anagrelide concentration in 
plasma for the 45 MPD patients was 1.6±1.2 ng/mL. 
There was no significant difference in anagrelide con-
centrations between PV and ET patients. Likewise, 
there was no significant difference between those who 
achieved CR or those with PR+F (not shown). Reliable 
methods for the measurement of anagrelide metabo-
lites were not available at the time of study.  
Effects on TPO and sIL-6R levels 
TPO 
PV and ET patients did not differ (p>0.05) at 
baseline with regard to their TPO levels. Also at six 
months the increments were similar in the two diag-
nosis groups (Table 1).   
The mean serum concentration of this cytokine 
increased with 44 % for all 45 MPD patients (P<0.00007 
compared to base-line values)(Table 1 and Figure 1). In 
CR patients, TPO levels rose slightly less, with 39.3 % 
(P=0.0024), whereas PR and failure patients displayed 
higher levels (57.7 %, P=0.013; Figure 1). Baseline TPO 
values were somewhat lower for CR patients com-
pared to the PR+F group (68.4±100 vs. 78.9±49.5 
pg/mL, respectively; p>0.05). Thus, the TPO concen-
tration at start did not indicate whether a patient 
would obtain CR or not. Likewise, there was no statis-
tically significant difference at 6 months between those 
achieving CR and those who did not (95.3±103 vs. 
124±90.7 pg/mL; P>0.05). 
Although the primary aim of this study was to 
assess changes of cytokines during anagrelide treat-Int. J. Med. Sci. 2008, 5 
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ment, some comparisons can be made with previously 
published studies as to levels of TPO of MPD patients 
compared to healthy individuals. Based on the studies 
by others, who used the same assay system as we have 
done [11, 23, 24], it appears that the starting TPO val-
ues for our MPD patients (mean values ± 2SD being 
0-250 pg/mL) were similar to those published for 
controls (combined mean values ± 2SD for the 3 stud-
ies: 0-221 pg/mL). The values at 6 months appeared, 
however, to be higher (92.5-302 pg/mL).  
sIL-6R 
PV and ET patients did neither differ at baseline 
nor at 6 months with regard to the sIL-6R levels (Table 
1). No significant changes were observed for this 
variable over the studied 6 months, neither for all pa-
tients, nor for those entering CR or PR+F (Figure 1). 
The mean ± 2SD values for our patients at start 
were slightly higher (28.6-58.3 ng/mL) than reported 
by Marta et al [30] for their control subjects, being 0-38 
ng/mL.  
Correlations 
There were no significant correlations (p>0.05) 
between the magnitude of the change of platelet 
counts, on the one hand, and changes of TPO or sIL-6R 
concentrations, on the other. Neither were there any 
significant correlations between changes of TPO or 
sIL-6R concentrations.  
Plasma anagrelide concentrations at 6 months did 
neither correlate to either platelet counts, TPO or 
sIL-6R concentrations at that time, nor to changes be-
tween time points 0 and 6 months for the latter three 
variables. 
Discussion 
We report here that serum levels of TPO, the 
major cytokine involved in the regulation of mega-
karyocyte and platelet growth and release, was raised 
at six months of anagrelide treatment; concomitantly 
there was a reduction of blood platelet counts. This rise 
in serum concentrations of TPO is a novel finding and 
may also be relevant for discussions about develop-
ment of bone marrow fibrosis during treatment with 
anagrelide [4, 27-29, 31].  
Previous investigations on TPO concentrations in 
chronic myeloproliferative disorders have shown that 
serum/plasma levels are slightly above or within the 
range of normal individuals [11-25]. Our results agree 
well with these previously published concentrations 
when the same assay, as we used here, has been em-
ployed. That is true for base-line values, whereas val-
ues after 6 months appear to be well over the reference 
range established by the others. Our findings might be 
of help to explain why TPO values were higher than 
normal in some studies and within the normal range in 
other; it might be a matter of effects related to previous 
treatments. 
We cannot offer any mechanistic explanation for 
why there was a rise in serum TPO levels. One specu-
lation relates to the model of action of TPO with its 
receptor on target cells. It is well established that se-
rum levels of TPO are regulated by the binding of the 
ligand to the receptor and the endocytosis of the 
ligand-receptor complex [9]. Against that background, 
we speculate that less TPO was bound to platelets and 
more remained free when anagrelide caused a reduc-
tion in platelet concentrations. This hypothesis is 
supported by the recent findings of McCarty et al, who 
showed an effect of anagrelide on CD41 numbers and 
TPO-specific pTyr activity in vitro, indicating that 
anagrelide reduces the TPO-mediated intracellular 
signaling events [10]. They suggest reduced receptor 
binding as a possible mechanism. Furthermore, the 
rise in TPO seen here may be analogous to what has 
been described for the opposite, viz. the drop in TPO 
that occurs when immunologic thrombocytopenic 
purpura patients respond to therapy with raised 
platelet counts. However, this hypothesis is not sup-
ported fully by the lack of correlation between the 
changes for platelet counts and TPO concentrations. 
Thus, those who displayed the most pronounced 
platelet count reduction and achieving CR had the 
lowest increase of TPO concentrations, whereas the 
PR+F group showed the most pronounced rise of TPO. 
Future studies of TPO interactions with its receptor, 
not only on platelets but also on megakaryocytes, 
might yield a better understanding [9]. 
One may ask if the TPO rise observed here was 
specific for the anagrelide treatment or if it might also 
be observed during treatment with hydroxyurea, 32P, 
interferon-α or other platelet reducing agents. At this 
time this is not known; future longitudinal studies may 
give an answer. However, the lack of correlation be-
tween TPO, on the one hand, and blood platelet 
counts, on the other, is in accordance with some pre-
vious results [13,19]. This lack also suggests that in-
teractions are rather complex or slow; thus, in samples 
obtained at a single time point it might not be feasible 
to demonstrate cause-effect relationships, even if such 
exist. Moreover, the lack of correlation between 
changes of levels of the here measured cytokines with 
levels of anagrelide is understandable, since the varia-
tion in maintenance dose was small (mean daily dose 
at 6 months 2.3±0.2 mg) and the number of patients is 
rather low. Moreover, recent data suggest that one 
metabolite, BCH 24426, retains the platelet lowering 
effect, whereas the other major metabolite, RL 603, 
does not [8, 32]. When reliable analyses of metabolites 
become available, such studies might shed some light Int. J. Med. Sci. 2008, 5 
 
90
on the drug-effect relations.  
Soluble IL-6 receptor (IL-6R) was recently advo-
cated as a protein susceptible to reductions during 
anagrelide treatment for MPD [30]. We can not cor-
roborate those findings here, despite using the same 
assay as those investigators. At this time no clear ex-
planation for the discrepancies of results can be of-
fered. 
Material and Methods  
Patients 
60 patients with a diagnosis of myeloproliferative 
disease were treated with anagrelide (Agrylin®)[3]. 17 
had polycythemia vera (PV), 42 essential thrombobo-
cythemia (ET) and 1 had myelofibrosis (MF). The di-
agnosis was established according to the diagnostic 
criteria of Pearson et al for polycythemia vera [33] or 
Kutti & Wadenvik [34] for essential thrombocythemia. 
The platelet count had to be >600 x 109/L in sympto-
matic patients or >1 000 x 109/L in all other patients at 
repeated measurements.  Symptoms were defined as 
previous thromboembolic episodes or ongoing micro-
circulatory symptoms  
The mean age was 52.7, median 53.5 (27-75) years 
for the whole group. Further details on demographics, 
previous treatments etc are given in [3]. The study was 
approved of the Ethical committee of Uppsala Univer-
sity and informed consent was obtained from all pa-
tients. 
Treatment and response criteria 
Full details of the treatment protocol are given in 
[3]. Anagrelide was administered orally. The starting 
dose was 0.5 mg b.i.d. If there was no response the 
dose was increased by 0.5 mg per day per week. The 
mean maintenance dose was 2.3 mg/day.  
Complete response (CR) was defined as fulfill-
ment of the treatment goal of a platelet count < 400 x 
109/L in symptomatic or <600 x 109/L in asympto-
matic patients, respectively, for at least 4 weeks. Partial 
response (PR) was defined as a reduction of the plate-
let count with at least 50 % of the baseline value, and 
treatment failure (F) as a reduction of the platelet count 
with < 50 % of the baseline value. Here, and for the 
purpose of cytokine levels and platelet counts, we have 
grouped PR and F together. 
Laboratory methods 
Blood counts were performed in the routine of 
the hospital laboratories of clinical chemistry.  
Serum and plasma samples were collected at 
baseline and after 6 months of therapy and stored at 
–70oC until analyzed. Only patients completing the 6 
months of therapy were included. 
Serum TPO and soluble IL-6 receptor (sIL-6R) 
c o n c e n t r a t i o n s  w e r e  m e a s u r e d  w i t h  E L I S A  ( Q u a n t i -
kine, R&D Systems, Minneapolis, MN), as recom-
mended by the manufacturer and in duplicates. The 
lower limits of detection were for TPO 8 pg/mL and 
for sIL-6R 6.5 pg/mL. There is no difference between 
serum and plasma levels of these two cytokines, ac-
cording to the information provided by the manufac-
turer.  
Anagrelide plasma concentrations were analyzed 
by York Bioanalytical Solutions, UK with a spectro-
metric method. 
Statistical methods 
Changes in concentration of cytokines were 
tested with T-test for dependent samples. Values are 
given as mean and SD values (or as indicated). Corre-
lations between variables were assessed with Pearson 
correlation test. 
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